Sales 116% 124% 106% 127% 138% 150% 114% 108% 110%

Expenses 96% 124% 119% 123% 120% 160% 111% 108% 111%
Operating Profit 447% 125% 59% 154% 245% 121% 124% 108% 110%
Net profit 562% 100% -22% -238% 399% 134% 129% 114% 105%
AUROBINDO PHARMA LTD SCREENER.IN

Narration Mar-09 Mar-10 Mar-11 Mar-12 Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18 Trailing Best Case Worst Case 1.01
Sales 3,022.82 3,515.35 4,368.45 4,615.10 5,842.41 8,088.67 12,103.29 13,771.66 14,909.54 16,463.03 17,386.87 18,240.86 18,274.64 1.21
Expenses 2,850.27 2,743.73 3,405.43 4,050.16 4,969.68 5,951.73 9,523.98 10,578.54 11,468.99 12,674.93 13,875.85 14,029.86 14,584.35 1.18
Operating Profit 172.55 771.62 963.02 564.94 872.73 2,136.94 2,579.31 3,193.12 3,440.55 3,788.10 3,511.02 4,210.99 3,690.29 1.41
Operating Profit % 5.71 21.95 22.04 12.24 14.94 26.42 21.31 23.19 23.08 23.01 20.19 23.09 20.19 1.17
Other Income 169.84 205.25 61.31 -300.12 16.76 18.27 81.02 200.25 114.64 88.77 121.35 - - 0.93
Other Income % 98% 27% 6% -53% 2% 1% 3% 6% 3% 2% 3% 0% 0% 0.66
EBIDT 342.39 976.87 1,024.33 264.82 889.49 2,155.21 2,660.33 3,393.37 3,555.19 3,876.87 3,632.37 4,210.99 3,690.29 1.31
EBIDT % 11.33 27.79 23.45 5.74 15.22 26.64 21.98 24.64 23.85 23.55 20.89 23.09 20.19 1.08
Depreciation 127.60 149.34 171.50 200.53 248.74 312.53 332.61 392.37 427.63 557.97 612.92 612.92 612.92 1.18
Interest 93.22 73.09 64.65 277.24 266.64 310.16 159.87 256.70 66.72 77.72 108.51 108.51 108.51 0.98
Interest Coverage Ratio 1.85 10.56 14.90 2.04 3.27 6.89 16.13 12.44 51.57 48.74 32.36 38.81 34.01 1.44
Profit before tax 121.57 754.44 788.18 -212.95 374.11 1,532.52 2,167.85 2,744.30 3,060.84 3,241.18 2,910.94 3,489.56 2,968.86 1.44
Profit before tax % 4.02 21.46 18.04 -4.61 6.40 18.95 17.91 19.93 20.53 19.69 16.74 19.13 16.25 1.19
Tax 21.36 191.36 225.12 -88.81 82.71 363.45 596.59 720.71 759.65 818.27 720.29 25% 25% 1.50
Tax % 17.57 25.36 28.56 41.70 22.11 23.72 27.52 26.26 24.82 25.25 24.74 0.01 0.01 1.04
Net profit 100.26 563.40 563.45 -123.50 293.86 1,172.85 1,575.77 2,025.09 2,301.66 2,423.17 2,190.61 2,626.10 2,234.24 1.42
Net profit % 3.32 16.03 12.90 -2.68 5.03 14.50 13.02 14.70 15.44 14.72 12.60 14.40 12.23 1.18
EPS 3.73 20.22 19.35 -4.24 10.09 40.24 53.97 34.61 39.29 41.36 37.39 44.82 38.13 1.31
Price to earning 5.66 4.67 5.06 -14.54 8.61 6.93 12.20 22.07 16.49 14.91 20.60 20.60 11.72 1.11
Price 21.11 94.35 98.02 61.69 86.88 278.72 658.16 763.63 647.76 616.79 770.05 923.13 446.86 1.45
#DIV/0!
RATIOS: #DIV/0!
Dividend Payout 24.13% 4.94% 10.33% 0.00% 14.86% 7.46% 8.34% 7.22% 6.36% 6.04% 0.86
OPM 5.71% 21.95% 22.04% 12.24% 14.94% 26.42% 21.31% 23.19% 23.08% 23.01% 20.19% 1.17

Price/Sales 0.70%
TRENDS: 10 YEARS 7 YEARS 5 YEARS 3 YEARS RECENT BEST WORST
Sales Growth 20.72% 20.87% 23.02% 10.80% 10.42% 10.80% 10.42%
OPM 21.32% 21.87% 23.17% 23.09% 20.19% 23.09% 20.19%
Price to Earning 11.72 14.54 15.53 18.52 20.60 20.60 11.72
Sales 100% 103% 93% 101% 121% 98% 93%
Expenses 99% 106% 97% 97% 117% 100% 99%
Operating Profit 104% 96% 81% 116% 134% 92% 77%
Net profit 104% 96% 92% 97% 151% 76% 89%
AUROBINDO PHARMA LTD SCREENER.IN

Narration Jun-16 Sep-16 Dec-16 Mar-17 Jun-17 Sep-17 Dec-17 Mar-18 Jun-18 Sep-18
Sales 3,766.59 3,775.45 3,906.18 3,641.63 3,678.75 4,435.89 4,336.11 4,049.09 4,250.27 4,751.40
Expenses 2,877.63 2,846.64 3,011.34 2,920.39 2,844.81 3,319.01 3,310.53 3,260.98 3,539.21 3,765.13
Operating Profit 888.96 928.81 894.84 721.24 833.94 1,116.88 1,025.58 788.11 711.06 986.27
Other Income 23.66 28.47 26.73 42.46 23.43 11.40 33.16 44.39 44.14 -0.34
Depreciation 106.24 110.20 111.14 100.05 131.18 132.08 138.08 156.63 154.53 163.68
Interest 20.64 17.54 14.26 14.28 16.87 17.27 18.86 24.72 29.54 35.39
Profit before tax 785.74 829.54 796.17 649.37 709.32 978.93 901.80 651.15 571.13 786.86
Tax 200.84 223.99 217.67 117.15 190.99 197.96 306.94 122.39 115.54 175.42
Net profit 584.96 605.64 578.59 532.45 518.51 781.15 595.01 528.51 455.66 611.43

OPM 24% 25% 23% 20% 23% 25% 24% 19% 17% 21%
AUROBINDO PHARMA LTD SCREENER.IN

Narration Mar-09 Mar-10 Mar-11 Mar-12 Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18
Equity Share Capital 26.88 27.86 29.11 29.11 29.12 29.15 29.20 58.52 58.59 58.59
Reserves 1,214.38 1,801.22 2,415.72 2,310.54 2,576.64 3,721.00 5,126.71 7,228.78 9,313.32 11,621.83
Total Shareholder Funds 1,241.26 1,829.08 2,444.83 2,339.65 2,605.76 3,750.15 5,155.91 7,287.30 9,371.91 11,680.42
Borrowings 2,332.97 2,154.56 2,414.25 3,095.94 3,435.46 3,769.14 4,451.07 5,041.07 3,364.14 4,769.94
Other Liabilities 652.24 807.67 1,013.20 802.04 1,374.51 1,989.09 3,336.05 3,612.92 3,847.43 5,035.21
Total 4,226.47 4,791.31 5,872.28 6,237.63 7,415.73 9,508.38 12,943.03 15,941.29 16,583.48 21,485.57
Debt/Equity Ratio 1.88 1.18 0.99 1.32 1.32 1.01 0.86 0.69 0.36 0.41
Current Ratio 2.91 2.64 2.84 3.56 2.71 2.61 2.28 2.62 1.98 2.03
Net Block 1,398.77 1,710.85 1,738.60 2,194.65 2,638.87 2,721.67 3,705.64 4,179.69 4,833.78 6,520.68
Capital Work in Progress 536.30 570.08 657.42 645.41 218.51 309.72 419.63 848.14 1,458.08 1,583.04
Investments 0.26 0.28 38.53 38.54 22.28 19.79 19.79 122.96 245.87 311.54
Other Assets 2,291.14 2,510.10 3,437.73 3,359.03 4,536.07 6,457.20 8,797.97 10,790.50 10,045.75 13,070.31
Total 4,226.47 4,791.31 5,872.28 6,237.63 7,415.73 9,508.38 12,943.03 15,941.29 16,583.48 21,485.57

Working Capital 1,638.90 1,702.43 2,424.53 2,556.99 3,161.56 4,468.11 5,461.92 7,177.58 6,198.32 8,035.10
Debtors 889.76 956.01 1,230.98 1,239.96 1,596.98 2,636.57 3,539.17 4,606.68 2,765.33 3,084.36
Inventory 877.63 1,102.45 1,455.27 1,545.56 1,923.59 2,367.54 3,611.30 4,056.14 4,330.54 5,858.41

Debtor Days 107.44 99.26 102.85 98.07 99.77 118.97 106.73 122.09 67.70 68.38
Inventory Turnover 3.44 3.19 3.00 2.99 3.04 3.42 3.35 3.40 3.44 2.81

Return on Equity 8% 31% 23% -5% 11% 31% 31% 28% 25% 21%
Return on Capital Emp 1% 13% 14% 10% 9% 20% 18% 18% 20% 17%
AUROBINDO PHARMA LTD SCREENER.IN

Narration Mar-09 Mar-10 Mar-11 Mar-12 Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18
Cash from Operating Activity 102.57 426.84 335.11 326.25 274.87 646.28 1,236.81 1,419.76 3,278.58 1,954.82 10,001.89 1.39
Cash from Investing Activity -406.28 -398.26 -603.10 -563.17 -245.87 -818.63 -1,016.94 -1,445.51 -1,787.18 -1,926.76 -9,211.70 1.19
Cash from Financing Activity 164.99 -84.04 406.98 118.85 108.09 117.64 93.21 365.44 -1,915.26 864.15 240.05 1.20
Net Cash Flow -138.72 -55.46 138.99 -118.07 137.09 -54.71 313.08 339.69 -423.86 892.21 1,030.24

Net profit 100.26 563.4 563.45 -123.5 293.86 1172.85 1575.77 2025.09 2301.66 2423.17 10,896.01 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
How to use it?
You can customize this workbook as you want.
You can add custom formating, add conditional formating, add your own formulas… do ANYTHING.
Please don't edit the "Data Sheet" only.

After customization, you can upload this back on Screener.

Upload on: https://www.screener.in/excel/

Download your customized workbooks now onwards.

Now whenever you will "Export to excel" from Screener, it will export your customized file.

TESTING:
This is a testing feature currently.
You can report any formula errors on the worksheet at: screener.feedback@dalal-street.in
… do ANYTHING.

dalal-street.in
COMPANY NAME AUROBINDO PHARMA LTD
LATEST VERSION 2.10 PLEASE
CURRENT VERSION 2.10

META
Number of shares 58.59
Face Value 1
Current Price 770.05
Market Capitalization 45117.82

PROFIT & LOSS

Report Date Mar-09 Mar-10 Mar-11 Mar-12
Sales 3,022.82 3,515.35 4,368.45 4,615.10
Raw Material Cost 1,627.82 1,906.00 2,379.44 2,525.82
Change in Inventory -8.92 184.92 206.42 6.06
Power and Fuel 182.72 194.91 208.26 232.36
Other Mfr. Exp 162.86 201.18 251.24 284.84
Employee Cost 243.67 327.28 425.07 535.69
Selling and admin 264.18 265.89 313.10 374.69
Other Expenses 360.10 33.39 34.74 102.82
Other Income 169.84 205.25 61.31 -300.12
Depreciation 127.60 149.34 171.50 200.53
Interest 93.22 73.09 64.65 277.24
Profit before tax 121.57 754.44 788.18 -212.95
Tax 21.36 191.36 225.12 -88.81
Net profit 100.26 563.40 563.45 -123.50
Dividend Amount 24.19 27.86 58.22 29.11

Quarters
Report Date Jun-16 Sep-16 Dec-16 Mar-17
Sales 3,766.59 3,775.45 3,906.18 3,641.63
Expenses 2,877.63 2,846.64 3,011.34 2,920.39
Other Income 23.66 28.47 26.73 42.46
Depreciation 106.24 110.20 111.14 100.05
Interest 20.64 17.54 14.26 14.28
Profit before tax 785.74 829.54 796.17 649.37
Tax 200.84 223.99 217.67 117.15
Net profit 584.96 605.64 578.59 532.45
Operating Profit 888.96 928.81 894.84 721.24
BALANCE SHEET
Report Date Mar-09 Mar-10 Mar-11 Mar-12
Equity Share Capital 26.88 27.86 29.11 29.11
Reserves 1214.38 1801.22 2415.72 2310.54
Borrowings 2332.97 2154.56 2414.25 3095.94
Other Liabilities 652.24 807.67 1013.2 802.04
Total 4,226.47 4,791.31 5,872.28 6,237.63
Net Block 1398.77 1710.85 1738.6 2194.65
Capital Work in Progress 536.3 570.08 657.42 645.41
Investments 0.26 0.28 38.53 38.54
Other Assets 2291.14 2510.1 3437.73 3359.03
Total 4,226.47 4,791.31 5,872.28 6,237.63
Receivables 889.76 956.01 1,230.98 1,239.96
Inventory 877.63 1102.45 1455.27 1545.56
Cash & Bank 127.65 72.83 186.72 70.86
No. of Equity Shares 53765268 55728837 291121290 291121290
New Bonus Shares
Face value 5 5 1 1

CASH FLOW:
Report Date Mar-09 Mar-10 Mar-11 Mar-12
Cash from Operating Activity 102.57 426.84 335.11 326.25
Cash from Investing Activity -406.28 -398.26 -603.10 -563.17
Cash from Financing Activity 164.99 -84.04 406.98 118.85
Net Cash Flow -138.72 -55.46 138.99 -118.07

PRICE: 21.11 94.35 98.02 61.69

DERIVED:
Adjusted Equity Shares in Cr 26.88 27.86 29.11 29.11
 PLEASE DO NOT MAKE ANY CHANGES TO THIS SHEET

Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18

5,842.41 8,088.67 12,103.29 13,771.66 14,909.54 16,463.03
3,261.02 3,708.04 5,835.08 6,254.98 6,743.46 7,235.26
270.25 102.00 329.48 92.88 309.20 482.52
324.72 349.84 359.60 419.26 437.14 470.95
315.81 428.43 537.57 590.06 644.50 745.63
663.31 802.43 1,302.26 1,542.62 1,767.76 2,130.84
550.27 708.29 1,632.91 1,684.89 1,969.34 2,270.44
124.80 56.70 186.04 179.61 215.99 304.33
16.76 18.27 81.02 200.25 114.64 88.77
248.74 312.53 332.61 392.37 427.63 557.97
266.64 310.16 159.87 256.70 66.72 77.72
374.11 1,532.52 2,167.85 2,744.30 3,060.84 3,241.18
82.71 363.45 596.59 720.71 759.65 818.27
293.86 1,172.85 1,575.77 2,025.09 2,301.66 2,423.17
43.68 87.45 131.40 146.30 146.47 146.47

Jun-17 Sep-17 Dec-17 Mar-18 Jun-18 Sep-18

3,678.75 4,435.89 4,336.11 4,049.09 4,250.27 4,751.40
2,844.81 3,319.01 3,310.53 3,260.98 3,539.21 3,765.13
23.43 11.40 33.16 44.39 44.14 -0.34
131.18 132.08 138.08 156.63 154.53 163.68
16.87 17.27 18.86 24.72 29.54 35.39
709.32 978.93 901.80 651.15 571.13 786.86
190.99 197.96 306.94 122.39 115.54 175.42
518.51 781.15 595.01 528.51 455.66 611.43
833.94 1116.88 1025.58 788.11 711.06 986.27
Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18
29.12 29.15 29.2 58.52 58.59 58.59
2576.64 3721 5126.71 7228.78 9313.32 11621.83
3435.46 3769.14 4451.07 5041.07 3364.14 4769.94
1374.51 1989.09 3336.05 3612.92 3847.43 5035.21
7,415.73 9,508.38 12,943.03 15,941.29 16,583.48 21,485.57
2638.87 2721.67 3705.64 4179.69 4833.78 6520.68
218.51 309.72 419.63 848.14 1458.08 1583.04
22.28 19.79 19.79 122.96 245.87 311.54
4536.07 6457.2 8797.97 10790.5 10045.75 13070.31
7,415.73 9,508.38 12,943.03 15,941.29 16,583.48 21,485.57
1,596.98 2,636.57 3,539.17 4,606.68 2,765.33 3,084.36
1923.59 2367.54 3611.3 4056.14 4330.54 5858.41
208.45 178.58 469.11 800.26 513.48 1261.62
291211290 291457020 291982275 585169586 585882409 585907609

1 1 1 1 1 1

Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18

274.87 646.28 1,236.81 1,419.76 3,278.58 1,954.82
-245.87 -818.63 -1,016.94 -1,445.51 -1,787.18 -1,926.76
108.09 117.64 93.21 365.44 -1,915.26 864.15
137.09 -54.71 313.08 339.69 -423.86 892.21

86.88 278.72 658.16 763.63 647.76 616.79

29.12 29.15 29.20 58.52 58.59 58.59